13:30 - 15:30

Engage & exchange tracks (still subject to change) 

• Financial Services
  
  Financial Services at the Inflection Point

Financial institutions are navigating unprecedented volatility, regulatory pressure and rising financial crime, while AI is rapidly evolving from experimentation to industrialized decision-making. 

This track explores how banks and insurers can create value in uncertain times by moving to governed, agentic and scalable AI. Through practical sessions on risk and regulatory management and fraud and financial crime prevention, you’ll gain concrete insights into how leading organizations modernize decision systems, strengthen resilience and deliver better outcomes with trusted AI. 

Agenda details coming soon.

• Public Sector & Healthcare
  
  
• Life Sciences 
  
  From Data to Decisions: Driving Value in Life Sciences with Trusted Data & AI

Life Sciences organizations face growing pressure to accelerate innovation, shorten development timelines and demonstrate real-world impact, all while navigating increasing regulatory and data complexity. With rapid advances in AI and analytics, the challenge is no longer whether to modernize, but where to focus first. 

In this session, hear from leaders from SAS, our partners and our customers on how trusted data, AI and advanced analytics are reshaping the life sciences landscape and enabling more confident decisions across the value chain and around the world. 

Agenda details coming soon. 

• Technical Users 
  
  
• Marketing Technology
  

From Data to Decisions: Driving Value in Life Sciences with Trusted Data & AI

Session will be moderated by SAS Dr. Mark Lambrecht and Luis Andre Soriano ,Senior Statistical Programmer , OCS Life Sciences

• Life Sciences organizations face growing pressure to accelerate innovation, shorten development timelines and demonstrate real-world impact, all while navigating increasing regulatory and data complexity. With rapid advances in AI and analytics, the challenge is no longer whether to modernize, but where to focus first. In this session, hear from leaders from SAS, our partners and our customers on how trusted data, AI and advanced analytics are reshaping the life sciences landscape and enabling more confident decisions across the value chain and around the world.

Presentation 1- Trust at Scale: How Data and AI Are Reshaping Life Sciences

• As Life Sciences organizations scale AI across research, development, and operations, trust becomes the defining requirement. In this presentation, SAS shares its vision for the future of life sciences - one where advanced analytics, AI, and governance are designed together. We will show how SAS supports customers across the Life Sciences value chain, enabling them to convert complex, regulated data into reliable, explainable insights that stand up to scientific, regulatory, and operational scrutiny.
  Dr. Mark Lambrecht, Global Head, SAS Health Care and Life Sciences Advisory

Presentation 2 Title: Modernizing Clinical Data Workflows: Real-World Insights from SAS Viya Evaluation

•  This paper presents a comprehensive evaluation of SAS Viya’s capabilities in transforming clinical data workflows within a biopharma context. Different Real-world use-cases—ranging from autoscaling and open-source integration to advanced biomarker analytics and model management—were implemented and assessed. The study highlights Viya’s impact on execution efficiency, interoperability with R and Databricks, and support for custom applications and dashboards. Key learnings include substantial reductions in processing time, seamless integration with open-source tools, and enhanced support for scalable, collaborative analytics. The findings inform best practices for migrating from legacy platforms to Viya, leveraging SAS Managed Cloud Services, for next-generation clinical data operations.
  
  Bjorn Daems, Director, Statistical Programing,  ArgenX

Presentation 3- Turn insights into actionable outcomes: Exploring how data, AI and RWE are shaping smarter clinical trial protocols.

• Clinical trials are evolving fast. Learn how trusted data, AI and real‑world evidence are enabling more efficient, patient‑centric trial protocols; Helping life sciences teams move from insight to action while navigating regulatory and data complexity.
  Dr. Margarita Mersiyanova, Sr Industry Consultant, SAS Life Sciences Advisory

Presentation 4 -Title: From Code Validation to Code Generation: A Human-Centered Generative AI Collaboration Between SGS and SAS

• SGS Pharma - Clinical Research and SAS have been collaborating to explore how generative AI can support clinical programming workflows.
  
  
• The initial phase of the collaboration focused on AI-assisted code validation, evaluating how generative AI can automate the review and verification of programming. The collaboration has since expanded to explore AI-driven code generation for common CDISC ADaM domains. Future areas of collaboration between SGS and SAS include automated generation of define.xml metadata, as well as support for more advanced efficacy domains.
  
  
• This presentation will share key lessons from AI-driven code validation and generation, and how these approaches can help improve efficiency while maintaining quality, transparency, and regulatory requirements. 
  Hoang  Van Thang, Biostatistician, SGS

Closing panel discussion

• Real Stories and Trusted Impact: Moving AI from Experiment to Enterprise in Life Sciences
  A forward-looking discussion on how Life Sciences organizations are turning  AI into a trusted operational capability - with governance that keeps models transparent, monitored and compliant from build through scale.
  Paul Vervuren, Principal Clinical Data Strategy at Danone